Mylan, Shire Battle Again Over Generic Vyvanse
Mylan Inc. and Johnson Matthey Inc. became the latest targets Thursday of drugmaker Shire LLC's ongoing efforts to protect its patents for the attention deficit hyperactivity disorder treatment Vyvanse....To view the full article, register now.
Already a subscriber? Click here to view full article